Kalydeco (IVacaftor) Patent Expiration, LOE Window & CMS Spending
Kalydeco (IVacaftor) by Vertex Pharmaceuticals: FDA Orange Book core substance LOE 2027-11-20 (last listed 2030-02-13), 0 AB generics, $104.7M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Vertex Pharmaceuticals |
| FDA Application & Pathway | N203188 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2027-11-20 |
| Last Listed Patent or Exclusivity Date | 2030-02-13 |
| Orange Book Patents (*PED Extensions) | 18 patents (9 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $104.7M |
| 2024 Medicare Part D Spend | $28.7M |
| 2024 Medicaid Spend | $75.9M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Vertex Pharmaceuticals across sibling Meru public-data platforms.